Patents and Inventions

Patents and Inventions

The Patents and Inventions Office implements appropriate strategies to protect inventions. It manages patent filing, prosecution and defense in Europe, USA and worldwide. The Office conducts patentability studies and freedom to operate searches, and participates in drafting priority filings as well as examination and opposition proceedings. The diversity of inventions represents a global asset which is protected by the Institut Pasteur to encourage the development and transfer of new technologies.


Protection statistics

By way of information, the Patents and Inventions Office manages more than 50 Invention Disclosures (ID) every year. The Office manages, extends and maintains a portfolio of more than 500 priority patents (about 2500 patents worldwide). Each year, this portfolio is gradually renewed with the filing of more than 20 new priority patent applications. The Office also uses other forms of protection such as deposits of biological materials at the National Collection of Microorganism Cultures (CNCM) and software protection. To date, the Institut Pasteur has made 1,479 deposits at the CNCM and 42 software and 112 know-how protection filings.


Key figures





Main partners




Among the portfolio, 1425 patents are co-owned with a majority for CNRS (300 patents) and INSERM (228 patents). Also, within these patents owned with partners, some patents are subject to multiple ownership which illustrates the scientific cooperation between many research organizations.


Through these patents, the Institut Pasteur also contributes to spreading new knowledge and technologies.



Examples of patent-protected inventions


WO2012/069657 (DI 2010-48)




Abstract: The present invention primarily concerns identification of a human gyrovirus HGyV, related to the chicken anemia virus (CAV). The present invention also relates to new proteins encoded by HGyV, which are homologs of CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is found in a human virus for the first time and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in biological samples.





Figure 6 shows a comparison between CAV and HGyV apoptin at the amino acid level. HGyV apoptin was aligned with its CAV homolog (accession number P54094).



PCT/EP2012074986 (DI 2012-13)


A multiplex immuno screening assay to detect the presence or absence of target antibodies in biological samples


Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with the enzyme substrate. This coupling is mediated by the irreversible reaction of the enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures. This allows to multiplex and minimize the amount of biological sample, and have enhanced sensitivity and specificity toward target antibodies as compared with classical ELISA or Radio-Immunoprecipitation assays. This new multiplex immuno screening assay is particularly useful in clinical and blood screening to detect viruses such as HBV, HCV, HIV1, HIV2, and WNV and prepare specific plates for emerging diseases as shown in the figure below.


Figure 11 shows an example of a 96-plate containing the antigen-coated microspheres of the invention adapted to run on Luminex system.




Updated on 19/02/2014